AI-Powered Protein Engineering Is Forcing Next-Gen IP Strategy and Competitive Analysis
Authors: Celeste Alvarez, Makda Gebre and Alex Harwig
AI isn’t just predicting 3D protein structures anymore; it is designing them from scratch.
AI-powered breakthrough systems, like AlphaFold and RosettaFold, revolutionized structure prediction, collapsing what once required years of crystallography or cryo-EM, into mere keystrokes – an achievement that helped secure the 2024 Chemistry Nobel Prize for computational protein design and structure prediction.
Protein engineering has shifted from wet-lab grind to algorithmic acceleration:
-
- Machine learning is teaming up with high-throughput biology to invent de novo therapeutics. Programs like RFdiffusion (Baker Lab) and AlphaDesign generate protein backbones and scaffolds entirely in silico, before experimental validation.
- Large Language Models (LLMs) are expanding sequence diversity at scale. ProGen2 (Profluent Bio) generated millions of new variants. Similarly, ESM3 (Meta/Flair) created esmGFP, a novel fluorescent protein validated in cells, proof that AI can invent functional proteins outside known sequence space
- Open-source tools like ProteinMPNN and RDdiffusion empower labs to generate hundreds of viable variants in a single afternoon.
This velocity is exhilarating for science but destabilizing for intellectual property (IP) strategy and competitive analysis.
The IP Dilemma
Traditional frameworks cannot match AI’s rapid pace:
-
- Patents can take years to obtain, while AI models iterate weekly.
- Manual freedom-to-operate searches can’t match the speed of AI-driven filings.
- Traditional trade secret protections assume stability, not evolving algorithms.
While innovation races ahead, protection lags behind. Pre-AI IP strategies must adapt to the evolving AI-powered world.
A New IP Calculus
The old “patent the sequences, keep know-how” playbook no longer suffices. AI workflows generate massive variant space before lab validation, shifting the strategic calculus.
Patents offer enforceable protection and attract licensing and investment, but they require public disclosure and are slow to issue. By the time claims are granted, the underlying model likely will be obsolete or designed around.
営業秘密, safeguard datasets, algorithms, and even “negative know-how” (failed experiments that guide future work). But protection evaporates once information leaks.
A hybrid model is emerging:
-
- Patent protection is pursued to protect validated protein compositions with clear therapeutic potential; and
- AI platforms, training data, and optimization workflows are held as trade secrets.
For instance, in de novo enzyme design, patents cover functional claims, while design algorithms remain as trade secrets. In antibody discovery, lead sequences are patented, while optimization steps and data on failed variants are held as trade secrets.
Disclosure is balanced with defense, transforming the IP landscape and demanding enhanced competitive intelligence.
Meeting Volume with AI
As AI multiplies both discoveries and filings, manual analysis becomes futile. Algorithmic discovery must be matched with algorithmic intelligence.
AI-powered patent search and analysis can identify subtle patterns across vast portfolios and track competitor capabilities. A project that would typically take months can be reduced to an afternoon.
Platforms like Fyled leverage AI to detect hidden competitive strategies, map patent portfolios, and track innovation in real time, helping academia and industry scientists navigate a landscape reshaped by the very technology transforming protein science.
About Fyled
Fyled rapidly translates complex science into IP intelligence, enabling IP professionals to scale their expertise and helping biotech and pharma uncover white space for innovation and drug repurposing. Learn more at Fyled.ai
Authors:
Celeste Alvarez, Principal Patent ConsultantMakda Gebre, Co-Founder at Fyled
Alex Harwig, CEO and Co-Founder at Fyled
Tangibly helps companies adapt their IP strategies for the AI era, protecting trade secrets and managing innovation at scale. Schedule a call with our experts.
